Current Report Filing (8-k)
February 12 2021 - 4:04PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): February 8, 2021
BIOTRICITY
INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
000-56074
|
|
47-2548273
|
(State
or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
275
Shoreline Drive, Suite 150
Redwood City, California 94065
(Address
of Principal Executive Offices)
(650)
832-1626
(Registrant’s Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
|
Securities
registered pursuant to Section 12(b) of the Act: note
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
Securities
registered pursuant to Section 12(b): None
|
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule
405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
|
|
|
|
|
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[X]
|
Item
2.02 Results of Operations and Financial Condition.
On
February 11, 2021, Biotricity Inc. (the “Company”) issued a press release reporting its financial results for the
period ended December 31, 2020. The press release is attached hereto as Exhibit 99.1.
In
accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1,
shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference
into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such filing.
Item 8.01. Other Events
On February 8, 2021,
the Company issued a press release announcing that it would be reporting its financial results for the quarter ended December
31, 2020. A copy of the press release is attached hereto as exhibit 99.2.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date:
February 12, 2021
|
|
BIOTRICITY
INC.
|
|
|
|
|
|
|
By:
|
/s/
John Ayanoglou
|
|
|
|
John
Ayanoglou
Chief
Financial Officer
|
Biotricity (QB) (USOTC:BTCY)
Historical Stock Chart
From Dec 2024 to Jan 2025
Biotricity (QB) (USOTC:BTCY)
Historical Stock Chart
From Jan 2024 to Jan 2025
